New Treatments and Trials
Migalastat HCl Clinical Development Update
Amicus and GlaxoSmithKline Rare Diseases (GSK-Rare Diseases) are currently developing migalastat HCl (AT1001/GR181413A) in Fabry disease and are investigating its safety and efficacy by conducting different clinical studies. The following studies are ongoing and currently enrolling.
AT1001-012: The ATTRACT Study: Read More